Avaliação da Eficácia do Cuidado Capilar para o Elixir Revitalizante Premium
Avaliação dos Efeitos do Elixir Revitalizante Premium nos Cuidados da Pele do Couro Cabeludo
The study aims to evaluate the efficacy of the Premium Revitalizing Elixir on human scalp skin. A total of 60 healthy adults, aged 18 to 60 with alopecia, baldness, or self-identified with symptoms of hair thinning will be recruited and randomly assigned into five groups receiving different formulations. Participants will use the product once daily for 56 days, and their scalp conditions will be assessed through skin texture tests at multiple time points. Key parameters such as sebum content, overall hair loss, hair density, scalp condition, and hair length will be measured. A self-assessment and assessment by a hair specialist on hair and scalp condition will also be provided at the end of the study (Day 56).
Visão geral do estudo
Status
Condições
Descrição detalhada
This is a prospective, randomized, double-blinded, and placebo-controlled study to investigate the effects of Premium Scalp Revitalizing Essence on changes in the skin texture of human scalp skin.
This study aims to enroll 60 healthy adults aged from 18 to 60 with alopecia, baldness, or self-identified with symptoms of hair thinning.
Inclusion criteria include healthy adults defined as individuals without chronic diseases, significant illnesses (including cancer, post-stroke disorders, paralysis, acute myocardial infarction, coronary artery bypass surgery, end-stage renal disease, and major organ transplant or hematopoietic stem cell transplant), or allergic constitutions, and who are not currently taking any medication or using any scalp care products.
Exclusion criteria include individuals who are pregnant or breastfeeding, as well as males or females with chronic diseases, significant illnesses, or allergic constitutions, currently using scalp care products, students or employees affiliated with the principal investigator, individuals with scalp wounds, those who have participated in cosmetic product testing, and those who have undergone scalp aesthetic treatments within the past three months.
The participants will be randomly assigned into five groups, with 12 individuals in each group. Group 1 uses Placebo (Base formula without caffeine and panthenol); Group 2 uses the Base formula (Control with 0.1% caffeine and panthenol); Group 3 uses Base + IGF-1 & FGF-7; Group 4 uses Base + Centella asiatica extracellular vesicles + Ginger-derived extracellular vesicles; Group 5 uses Base + Centella asiatica extracellular vesicles + Ginger-derived extracellular vesicles + IGF-1 & FGF-7 (each growth factor at twice the concentration than that in Group 3). Before using the test product, all 60 participants undergo the first scalp skin texture test. After 14 days of using the test product, a second scalp skin texture test is conducted; after 28 days of use, a third test is performed; after 42 days of use, a fourth test is conducted; and after 56 days of use, a fifth test is carried out. The scalp skin texture tests include measurements of skin (1) sebum content, (2) overall hair loss, (3) hair density, (4) scalp condition, (5) hair length, and other parameters. The Sebumeter® SM815 probe of the MPA580 device and the ScalpX Intelligent Scalp Diagnostic System will be used to measure the parameters of the study. On Day 56, the participants will be asked to fill out a self-assessment form and a hair specialist will also assess the hair and scalp condition at the end of the study.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Taichung, Taiwan, 433304
- Hungkuang University
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Healthy adults of any gender from the age of 18 to 60 years (inclusive).
- Having symptoms of alopecia, baldness, or self-identified with hair thinning.
- Absence of chronic diseases, major illnesses, or allergies.
- Major illnesses include cancer, post-stroke disorders, paralysis, acute myocardial infarction, coronary artery bypass surgery, end-stage renal disease, and major organ transplant or hematopoietic stem cell transplant
Exclusion Criteria:
- Currently taking any medication or using any scalp care products
- Pregnant or breastfeeding
- Chronic diseases, significant illnesses, or allergic constitutions
- Currently using scalp care products
- Students or employees affiliated with the principal investigator,
- Individuals with scalp wounds
- Participated in cosmetic product testing
- Undergone scalp aesthetic treatments within the past three months.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Group 1: Placebo control
Base formula without caffeine and panthenol |
Placebo control (base formula without caffeine and panthenol). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days. |
|
Experimental: Group 2: Base formula only
Base formula consisting of active ingredients 0.1% caffeine and panthenol (vitamin B5). |
Base formula consisting of active ingredients 0.1% caffeine and panthenol. Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days. |
|
Experimental: Group 3: Base formula plus IGF-1 & FGF-7.
Base formula plus insulin growth factor-1 (IGF-1, 250 ng/mL) and fibroblast growth factor-7 (FGF-7, 150 ng/mL) |
Base formula plus insulin growth factor-1 (IGF-1, 250 ng/mL) and fibroblast growth factor-7 (FGF-7, 150 ng/mL). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days. |
|
Experimental: Group 4: Base formula plus Centella asiatica and ginger extracellular vesicles
Base formula plus Centella asiatica and ginger (Zingiber officinale) extracellular vesicles (1E9 particles/mL) |
Base formula plus Centella asiatica and ginger extracellular vesicles (1E9 particles/mL). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days. |
|
Experimental: Group 5: Base formula plus Centella asiatica and ginger extracellular vesicles, IGF-1 & FGF-7.
Base formula plus Centella asiatica and ginger (Zingiber officinale) extracellular vesicles (both 1E9 particles/mL), insulin growth factor-1 (IGF-1, 500 ng/mL) and fibroblast growth factor-7 (FGF-7, 300 ng/mL) |
Base formula plus Centella asiatica and ginger extracellular vesicles (both 1E9 particles/mL), insulin growth factor-1 (IGF-1, 500 ng/mL) and fibroblast growth factor-7 (FGF-7, 300 ng/mL). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Sebum Content
Prazo: Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0 as baseline)
|
Assess oil levels on the scalp at standardized scalp sites (left, right, and vertex). Measured with C+K Multi Probe Adaptor MPA580 system using the Sebumeter® SM815 probe based on the grease spot photometry method with the sebum measurement cassette tape. |
Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0 as baseline)
|
|
Hair length
Prazo: Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0 as baseline)
|
Hair length (cm): Measured manually with ruler at standardized scalp sites (left, right, and vertex). |
Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0 as baseline)
|
|
Hair density
Prazo: Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0 as baseline)
|
Hair density (number of hairs/cm-square): Assessed with the ScalpX Intelligent Scalp Diagnostic System with digital microscopy at standardized scalp sites (left, right, and vertex). |
Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0 as baseline)
|
|
Hair thickness
Prazo: Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0 as baseline)
|
Hair thickness (micrometers): Assessed with the ScalpX Intelligent Scalp Diagnostic System with digital microscopy at standardized scalp sites (left, right, and vertex). |
Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0 as baseline)
|
|
Hair loss
Prazo: Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0)
|
Hair loss: Assessed by the standardized hair combing test by counting the number of hairs shed after the participants' hair was combed over a clean surface for 60 strokes. |
Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Participant self-assessment
Prazo: Day 56 (End of the study period)
|
Participants will be asked to fill out an assessment form with score from 0 to 4 for each of the hair and scalp condition evaluated. |
Day 56 (End of the study period)
|
|
Hair specialist assessment
Prazo: Day 56 (End of the study)
|
A hair specialist will assess the hair and scalp condition of the participant and assign a score from 0 to 4 for each of the evaluated items as well as assign a score of Global Aesthetic Improvement Scale (GAIS) from -1 to 3. |
Day 56 (End of the study)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Condições Patológicas, Anatômicas
- Doenças de pele
- Hipotricose
- Doenças do cabelo
- Condições Patológicas, Sinais e Sintomas
- Doenças da Pele e do Tecido Conjuntivo
- Alopecia
- Peptídeos
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Fatores biológicos
- Proteínas sanguíneas
- Somatomedinos
- Peptídeos semelhantes a insulina
- Peptídeos e proteínas de sinalização intercelular
- Fator de crescimento semelhante à insulina I
- Extrato de Centella asiatica
Outros números de identificação do estudo
- 25-090-A
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .